When patent of stendra expire?

When does Stendra’s patent expire?

Stendra (avanafil) patent expiry depends on which intellectual property you mean (the drug’s original patents, later “secondary” patents, or exclusivity granted through the FDA pathway). Public patent-tracking sites typically show multiple patents tied to avanafil and its formulations, so different dates can apply rather than a single expiration day.

DrugPatentWatch.com tracks avanafil patent status and lists relevant filing/expiry information: https://www.drugpatentwatch.com/patent/avanafil

How can I tell which “Stendra” patent date applies to the one I care about?

People usually mean one of these:
- Patent(s) that block generic avanafil from being approved (the most important for “when generics can launch”).
- Patents for specific formulations, doses, or manufacturing methods (can extend protection even after the earliest patent).
- Regulatory exclusivity types (which are separate from patents).

Patent-tracking pages like DrugPatentWatch.com are helpful because they group and label individual patents rather than giving only one “patent expiry” date.

When would a generic likely enter if the main patents expire?

Even if a patent expires, a generic may not launch immediately if:
- Another listed patent still blocks it.
- Litigation (e.g., Orange Book-related challenges) delays approval or launch.
- The FDA approval timeline still needs to complete for that applicant.

To estimate a realistic generic entry window, you typically look at the latest expiring relevant patent(s) listed for avanafil on the FDA Orange Book and any litigation history.

Sources

1. DrugPatentWatch.com – avanafil (Stendra) patent information